These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20). Burrows N; Cane G; Robson M; Gaude E; Howat WJ; Szlosarek PW; Pedley RB; Frezza C; Ashcroft M; Maxwell PH Sci Rep; 2016 Mar; 6():22950. PubMed ID: 26972697 [TBL] [Abstract][Full Text] [Related]
9. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells. Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391 [TBL] [Abstract][Full Text] [Related]
10. Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy. Long Y; Tsai WB; Wang D; Hawke DH; Savaraj N; Feun LG; Hung MC; Chen HH; Kuo MT Cancer Lett; 2017 Mar; 388():54-63. PubMed ID: 27913198 [TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression. Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153 [TBL] [Abstract][Full Text] [Related]
12. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Allen MD; Luong P; Hudson C; Leyton J; Delage B; Ghazaly E; Cutts R; Yuan M; Syed N; Lo Nigro C; Lattanzio L; Chmielewska-Kassassir M; Tomlinson I; Roylance R; Whitaker HC; Warren AY; Neal D; Frezza C; Beltran L; Jones LJ; Chelala C; Wu BW; Bomalaski JS; Jackson RC; Lu YJ; Crook T; Lemoine NR; Mather S; Foster J; Sosabowski J; Avril N; Li CF; Szlosarek PW Cancer Res; 2014 Feb; 74(3):896-907. PubMed ID: 24285724 [TBL] [Abstract][Full Text] [Related]
13. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy. McAlpine JA; Lu HT; Wu KC; Knowles SK; Thomson JA BMC Cancer; 2014 Aug; 14():621. PubMed ID: 25164070 [TBL] [Abstract][Full Text] [Related]
14. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1. Locke M; Ghazaly E; Freitas MO; Mitsinga M; Lattanzio L; Lo Nigro C; Nagano A; Wang J; Chelala C; Szlosarek P; Martin SA Cell Rep; 2016 Aug; 16(6):1604-1613. PubMed ID: 27452468 [TBL] [Abstract][Full Text] [Related]
16. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation. Long Y; Tsai WB; Chang JT; Estecio M; Wangpaichitr M; Savaraj N; Feun LG; Chen HH; Kuo MT Oncotarget; 2016 Dec; 7(50):82658-82670. PubMed ID: 27765932 [TBL] [Abstract][Full Text] [Related]
17. BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification. Barnett SE; Kenyani J; Tripari M; Butt Z; Grosman R; Querques F; Shaw L; Silva LC; Goate Z; Marciniak SJ; Rassl DM; Jackson R; Lian LY; Szlosarek PW; Sacco JJ; Coulson JM Mol Cancer Res; 2023 May; 21(5):411-427. PubMed ID: 36669126 [TBL] [Abstract][Full Text] [Related]
18. Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment. Rogers LC; Kremer JC; Brashears CB; Lin Z; Hu Z; Bastos ACS; Baker A; Fettig N; Zhou D; Shoghi KI; Dehner CA; Chrisinger JSA; Bomalaski JS; Garcia BA; Oyama T; White EP; Van Tine BA Clin Cancer Res; 2023 Aug; 29(16):3189-3202. PubMed ID: 37339179 [TBL] [Abstract][Full Text] [Related]
19. A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma. Hall PE; Lewis R; Syed N; Shaffer R; Evanson J; Ellis S; Williams M; Feng X; Johnston A; Thomson JA; Harris FP; Jena R; Matys T; Jefferies S; Smith K; Wu BW; Bomalaski JS; Crook T; O'Neill K; Paraskevopoulos D; Khadeir RS; Sheaff M; Pacey S; Plowman PN; Szlosarek PW Clin Cancer Res; 2019 May; 25(9):2708-2716. PubMed ID: 30796035 [TBL] [Abstract][Full Text] [Related]
20. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Delage B; Fennell DA; Nicholson L; McNeish I; Lemoine NR; Crook T; Szlosarek PW Int J Cancer; 2010 Jun; 126(12):2762-72. PubMed ID: 20104527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]